{
      "Rank": 473,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
            "Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
            "Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients"
      ],
      "ArmGroupInterventionName": [
            "Biological: Placenta-derived MMSCs",
            "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
            "Biological: Bone marrow-derived MMSCs",
            "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
            "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe"
      ],
      "ArmGroupLabel": [
            "Hyaluronic Acid (HA) + P-MMSCs",
            "Hyaluronic Acid (HA) + BM-MMSCs",
            "Hyaluronic Acid (HA)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04453111"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "To define the clinical effects of intra-articular transplantation of bone-marrow-derived (BM-MMSCs) and placenta-derived multipotent mesenchymal stem / stromal cells (P-MMSCs) for knee osteoarthritis."
      ],
      "BriefTitle": [
            "Efficacy of Bone-marrow-derived and Placenta-derived Multipotent Mesenchymal Stem / Stromal Cells for Osteoarthritis"
      ],
      "CentralContactEMail": [
            "nemtinov@stemcellclinic.com",
            "kyryk@stemcellclinic.com"
      ],
      "CentralContactName": [
            "Peter Nemtinov, MD",
            "Vitalii Kyryk, MD, PhD"
      ],
      "CentralContactPhone": [
            "+380442079207",
            "+380442079207"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "UNKNOWN",
            "UNKNOWN"
      ],
      "CollaboratorName": [
            "The Institute of Traumatology and Orthopedics of NAMS of Ukraine",
            "Kyiv City Clinical Hospital \u2116 6"
      ],
      "CompletionDate": [
            "October 2021"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Knee Osteoarthritis"
      ],
      "ConditionAncestorId": [
            "D000001168",
            "D000007592",
            "D000009140",
            "D000012216"
      ],
      "ConditionAncestorTerm": [
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "All",
            "BC17"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "All Conditions",
            "Skin and Connective Tissue Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Osteoarthritis",
            "Knee Osteoarthritis"
      ],
      "ConditionBrowseLeafId": [
            "M12078",
            "M21321",
            "M3628",
            "M9773",
            "M11249",
            "M14197",
            "M5475"
      ],
      "ConditionBrowseLeafName": [
            "Osteoarthritis",
            "Osteoarthritis, Knee",
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Collagen Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000010003",
            "D000020370"
      ],
      "ConditionMeshTerm": [
            "Osteoarthritis",
            "Osteoarthritis, Knee"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [
            "Experimental: HA + stem cells therapy Experimental Group 1: three intra-articular injection of allogeneic P-MMSCs with up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients Experimental Group 2: three intra-articular injection of autologous BM-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients Control Group: three intra-articular injection of 20 mg Hyaluronic Acid, no cell therapy - 15 patients"
      ],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Multipotent mesenchymal stem / stromal cells (MMSCs) of different origin are the novel therapeutic agents that can slow down cartilage degeneration, improve reparation and ultimately prevent joint prosthetics. MSCs are capable to direct differentiation into chondrocytes, produce cytokines and growth factors with immunomodulatory and anti-inflammatory effects, stimulate angiogenesis, as well as induce chemotaxis of endogenous progenitors. Bone marrow-derived and placenta-derived MMSCs can be considered the most promising source for cell therapy of joints disorders according to availability, safety and expected therapeutic efficacy."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nClinical diagnosis of knee osteoarthritis.\nAge: 18 to 75 years old.\nKellgren-Lawrence Grade 2 or 3 according to X-ray imaging.\nKnee pain.\nWritten informed consent\n\nExclusion Criteria:\n\nAge <18 or >75 years of age by time of infusion.\nParticipation in an on-going investigational therapeutic or device trial 30 days of consent.\nRheumatoid arthritis.\nPsoriatic arthritis.\nJuvenile idiopathic arthritis.\nGout.\nInfectious arthritis.\nOsteomyelitis.\nOsteonecrosis.\nInflammatory arthritis.\nChondropathy.\nJoint contracture.\nArthroplasty.\nArthroscopy within 6 months prior to study entry.\nIntra-articular injection within 3 months prior to study entry.\nHormone intake.\nAntiaggregants and anticoagulants intake.\nImmunosuppressants intake.\nAllergy to hyaluronic acid.\nHistory of organ or cell transplantation.\nHematologic abnormality evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet count < 100,000/ul.\nActive infection.\nPositive for HIV antigen.\nHistory of hepatitis B, hepatitis C.\nHistory of malignancy in the last 5 years prior to study entry.\nActive tumors.\nHistory of myocardial infarction.\nHistory of stroke.\nRenal failure with chronic hemodialysis.\nLiver Cirrhosis (ICGR 15 >30%).\nChromosomal abnormality.\nPeripheral nervous system disorders.\nCognitive or language barriers that prohibit obtaining informed consent or any study elements.\nHistory of drug abuse or alcohol abuse, or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months.\nPregnant/nursing women or women of child-bearing potential.\nOther condition that limits lifespan to < 1 year."
      ],
      "EnrollmentCount": [
            "45"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000276",
            "D000007155",
            "D000045505",
            "D000055675",
            "D000020011"
      ],
      "InterventionAncestorTerm": [
            "Adjuvants, Immunologic",
            "Immunologic Factors",
            "Physiological Effects of Drugs",
            "Viscosupplements",
            "Protective Agents"
      ],
      "InterventionArmGroupLabel": [
            "Hyaluronic Acid (HA) + P-MMSCs",
            "Hyaluronic Acid (HA) + BM-MMSCs",
            "Hyaluronic Acid (HA)",
            "Hyaluronic Acid (HA) + BM-MMSCs",
            "Hyaluronic Acid (HA) + P-MMSCs"
      ],
      "InterventionBrowseBranchAbbrev": [
            "All"
      ],
      "InterventionBrowseBranchName": [
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Fetal heart rate"
      ],
      "InterventionBrowseLeafId": [
            "M9030",
            "M2780",
            "M9353",
            "M27448",
            "M21022"
      ],
      "InterventionBrowseLeafName": [
            "Hyaluronic Acid",
            "Adjuvants, Immunologic",
            "Immunologic Factors",
            "Viscosupplements",
            "Protective Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells",
            "Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells",
            "Hyaluronic Acid 20 mg"
      ],
      "InterventionMeshId": [
            "D000006820"
      ],
      "InterventionMeshTerm": [
            "Hyaluronic Acid"
      ],
      "InterventionName": [
            "Placenta-derived MMSCs",
            "Bone marrow-derived MMSCs",
            "Hyalgan 20 mg in 2 ML Prefilled Syringe"
      ],
      "InterventionOtherName": [
            "P-MMSCs",
            "BM-MMSCs",
            "HA"
      ],
      "InterventionType": [
            "Biological",
            "Biological",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "BM-MMSCs;",
            "P-MMSCs;",
            "Hyaluronic Acid"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Recruiting"
      ],
      "LastUpdatePostDate": [
            "July 7, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "July 1, 2020"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Institute of Cell Therapy"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Kyiv"
      ],
      "LocationContactEMail": [
            "nemtinov@stemcellclinic.com",
            "kyryk@stemcellclinic.com"
      ],
      "LocationContactName": [
            "Peter Nemtinov, MD",
            "Vitalii Kyryk, PhD",
            "Evgen Goliuk, MD, PhD",
            "Roman Birsa, MD"
      ],
      "LocationContactPhone": [
            "+380442079207",
            "+380442079207"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "LocationCountry": [
            "Ukraine"
      ],
      "LocationFacility": [
            "Institute of Cell Therapy"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "04073"
      ],
      "MaximumAge": [
            "75 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Efficacy of Bone-marrow-derived and Placenta-derived Multipotent Mesenchymal Stem / Stromal Cells for Osteoarthritis"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Institute of Cell Therapy"
      ],
      "OrgStudyId": [
            "#7/09.26.2018"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Institute of Cell Therapy"
      ],
      "OverallOfficialName": [
            "Peter Nemtinov, MD"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "August 2021"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Treatment-related adverse events"
      ],
      "PrimaryOutcomeMeasure": [
            "Number of participants with adverse events and changes in physical examinations, vital signs and the results of clinical lab tests."
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Change in joint function from baseline WOMAC assessment. The WOMAC used a scoring scale of 0-4 (lower scores indicate lower levels of symptoms or physical disability). The higher the score, the higher the amount of pain, stiffness, and a high level of functional limitations.",
            "Change in cartilage thickness of the knee using MRI",
            "Change in scores on the QOL",
            "VAS - measure of pain intensity. The scale is most commonly anchored by \"no pain \" (score of 0) and \"worst imaginable pain\" (score of 10)."
      ],
      "SecondaryOutcomeMeasure": [
            "Physical function improvement measured by Western Ontario and McMaster Universities Arthritis Index (WOMAC).",
            "Radiographic evidence. Whole-Organ Magnetic Resonance Imaging Score (WORMS)",
            "Quality of Life (QOL) assessment",
            "The Visual Analog Scale (VAS) assessment"
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 months.",
            "12 months",
            "12 months",
            "12 months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "January 2, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "July 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "July 1, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "June 15, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "June 26, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}